title: Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014.
abstract: Scientists working in the field of Alzheimer's disease and, in particular, cognitive enhancers, are very productive. The review "Drugs interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs" was accepted in October 2012. In the last 20 months, new targets for the potential treatment of Alzheimer's disease were identified. Enormous progress was realized in the pharmacological characterization of natural products with cognitive enhancing properties. This review covers the evolution of research in this field through May 2014.
authors: AC Immune SA, EPFL, Lausanne, Switzerland.
authors: Wolfgang
authors: W
authors: Froestl
authors: AC Immune SA, EPFL, Lausanne, Switzerland.
authors: Andrea
authors: A
authors: Pfeifer
authors: AC Immune SA, EPFL, Lausanne, Switzerland.
authors: Andreas
authors: A
authors: Muhs
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000503:physiopathology; D000818:Animals; D006801:Humans; D018697:Nootropic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D018697:Nootropic Agents
keywords: Amyloid-β aggregation inhibitors; antibodies; antioxidants; cognitive enhancers; metal chelators; natural products; nootropics; peptides; psychostimulants; stem cells; tau; vaccines